Head-to-head · Cost-Efficiency Index
Trimrose vs VigorMeds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Trimrose
Shoppers who want a named medical director and pharmacy partners plus the option to step up to branded GLP-1s on the same platform.
Visit TrimroseVigorMeds
Cost-first shoppers who want a needle-free sublingual GLP-1 that's meaningfully cheaper than the injectable version, from named physicians.
Visit VigorMedsThe verdict
Trimrose and VigorMeds tie on the Cost-Efficiency Index at 50/100, so neither wins outright on the numbers. For most shoppers we'd start with Trimrose (ranked #415, a hair above #416) — Shoppers who want a named medical director and pharmacy partners plus the option to step up to branded GLP-1s on the same platform. But VigorMeds is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Trimrose.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Trimrose | VigorMeds |
|---|---|---|
| Cost-Efficiency Index | 50/100 | 50/100 |
| Semaglutide / mo | $269/mo (starting dose, compounded) | $199/mo (starting dose, compounded) |
| Tirzepatide / mo | $359/mo (starting dose, compounded) | $299/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $3,228 | $2,388 |
| Tirzepatide / yr (modeled) | $4,308 | $3,588 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #415 | #416 |
Trimrose
50/100Where the value is
- LegitScript-verified with a displayed seal
- Named medical directors with public NPI numbers, unusual transparency versus peers
- Four named, identifiable compounding pharmacy partners
The tradeoffs
- All prices are 'starting at' floors -- actual monthly cost rises with dose and is not fully disclosed upfront
- A separate $60 first-visit fee is layered on top of the monthly medication price
VigorMeds
50/100Where the value is
- Both injectable and needle-free sublingual forms of semaglutide ($139/mo) and tirzepatide ($159/mo) — the sublingual tier is $60-$140/mo cheaper than the injectable tier
- Named, credentialed clinicians reviewing cases: Dr. Anthony Kane MD, Dr. Claudia Mondragon MD, Dr. Kevin Kargman MD, Stephanie Kowatch MSN FNP-C
- 'Pay upon medical approval' — no charge until a provider signs off on treatment, plus a 30-day satisfaction guarantee
The tradeoffs
- The dedicated 'States We Serve' page names zero actual states in its crawlable content — only vague buckets like 'Coming soon' and 'Room to grow'
- The FIRST100 promo code discounts whichever tier is chosen by $100 for the first month, so the price shown at signup is not the ongoing rate
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.